Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol

Heart and Vessels

Volumn 29, Issue 1, 2014, Pages 35-41

  Ogita, Manabu ^a   Miyauchi, Katsumi ^a   Miyazaki, Tadashi ^a   Naito, Ryo ^a   Konishi, Hirokazu ^a   Tsuboi, Shuta ^a   Dohi, Tomotaka ^a   Kasai, Takatoshi ^a   Yokoyama, Takayuki ^a   Okazaki, Shinya ^a   Kurata, Takeshi ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Coronary intervention; Diabetes; Low HDL C; Residual risk factor

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE CONTROL; FEMALE; FOLLOW UP; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL PREDICTION; SURVIVAL RATE;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE-FREE SURVIVAL; DOWN-REGULATION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899091272     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-013-0330-5     Document Type: Article

References (43)

1. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease: the Framingham Study. JAMA 241:2035-2038 (Pubitemid 9228506)
2. Bloomgarden ZT (2008) Cardiovascular disease in diabetes. Diabetes Care 31:1260-1266
3. Preis SR, Hwang SJ, Coady S, Pencina MJ, D'Agostino RB Sr, Savage PJ, Levy D, Fox CS (2009) Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 119:728-1735
4. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J (1998) Impact of diabetes onmortality after the first myocardial infarction. The FINMONICA myocardial infarction register study group. Diabetes Care 21:69-75 (Pubitemid 28030388)
5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234 (Pubitemid 28350165)
6. Nasu K, Tsuchikane E, Kato O, Fujita H, Surmely JF, Ehara M, Kinoshita Y, Tanaka N, Matsubara T, Asakura Y, Terashima M, Suzuki T (2008) Plaque characterization by Virtual Histology intravascular ultrasound analysis in patients with type 2 diabetes. Heart 94:429-433 (Pubitemid 351441396)
7. Mineoka Y, Fukui M, Tanaka M, Tomiyasu K, Akabame S, Nakano K, Yamazaki M, Hasegawa G, Oda Y, Nakamura N (2012) Relationship between cardio-ankle vascular index (CAVI) and coronary artery calcification (CAC) in patients with type 2 diabetes mellitus. Heart Vessels 27:160-165
8. Farrag A, Bakhoum S, Salem MA, El-Faramawy A, Gergis E (2011) The association between extracoronary calcification and coronary artery disease in patients with type 2 diabetes mellitus. Heart Vessels. doi: 10.1007/s00380-011- 0205-6
9. Flaherty JD, Davidson CJ (2005) Diabetes and coronary revascularization. JAMA 293:1501-1508 (Pubitemid 40393296)
10. Kasai T, Miyauchi K, Kajimoto K, Kubota N, Kurata T, Daida H (2008) Influence of diabetes on >10-year outcomes after percutaneous coronary intervention. Heart Vessels 23:149-154 (Pubitemid 351722404)
11. Colhoun HM, Bettteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, on behalf of the CARDS investigators (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDs): multicenter randomized placebo-controlled trial. Lancet 364:685-696 (Pubitemid 39140624)
12. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361:2005-2016
13. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256:2835-2838 (Pubitemid 17178361)
14. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W, Atherosclerosis Risk in Communities Study Group (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104:1108-1113 (Pubitemid 32830392)
15. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 53:450-467
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497
17. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M (2007) Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14:45-50
18. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982-992
19. The Examination Committee of Criteria for Metabolic Syndrome (2005) Definition and criteria of metabolic syndrome. J Jpn Soc Int Med 94:794-809 (in Japanese)
20. Oda E, Watanabe K (2006) Japanese criteria of metabolic syndrome. Circ J 70:364
21. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301:2129-2140
22. Jacobs MJ, Kleisli T, Pio JR, Malik S, L'ltalien GJ, Chen RS, Wong ND (2005) Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 70:263-269 (Pubitemid 41539788)
23. Bruckert E, Baccara-Dinet M, Eschwege E (2007) Low HDL-cholesterol is common in European type 2 diabetic patients receiving treatment for dyslipidemia: data from a pan-European survey. Diabet Med 24:388-391 (Pubitemid 46452407)
24. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC, Treating to New Targets Investigators (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357:1301-1310 (Pubitemid 47481452)
25. Goldbourt U, Yaari S, Medalie JH (1997) Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 17:107-113 (Pubitemid 27057331)
26. Miller M, Kwiterovich PO Jr (1990) Isolated low HDL cholesterol as an important risk factor for coronary heart disease. Eur Heart J Suppl H:9-14
27. Ueshima H, Iida M, Shimamoto T, Konishi M, Tanigaki M, Nakanishi N, Takayama Y, Ozawa H, Kojima S, Komachi Y (1982) High-density lipoprotein-cholesterol levels in Japan. JAMA 247:1985-1987 (Pubitemid 12133711)
28. Ko M, Kim MT, Nam JJ (2006) Assessing risk factors of coronary heart disease and its risk prediction among Korean adults: the 2001 Korea National Health and Nutrition Examination Survey. Int J Cardiol 110:184-190 (Pubitemid 43767100)
29. Heng D, Ma S, Lee JJ, Tai BC, Mak KH, Hughes K, Chew SK, Chia KS, Tan CE, Tai ES (2006) Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 186:367-373 (Pubitemid 44269072)
30. Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Ueshima H, The NIPPON DATA90 Research Group (2006) The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis 184:143-150 (Pubitemid 41721081)
31. Huxley RR, Barzi F, Lam TH, Czernichow S, Fang X, Welborn T, Shaw J, Ueshima H, Zimmet P, Jee SH, Patel JV, Caterson I, Perkovic V, Woodward M, for the Asia Pacific Cohort Studies Collaboration and the Obesity in Asia Collaboration (2011) Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation 124:2056-2064
32. Seo SM, Choo EH, Koh YS, Park MW, Shin DI, Choi YS, Park HJ, Kim DB, Her SH, Lee JM, Park CS, Kim PJ, Moon KW, Chang K, Kim HY, Yoo KD, Jeon DS, Chung WS, Park YG, Seung KB, Catholic University of Korea, Percutaneous Coronary Intervention Registry Investigators (2011) High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart 97:1942-1950
33. Betteridge DJ (2011) Lipid control in patients with diabetes mellitus. Nat Rev Cardiol 8:278-290
34. Natarajan P, Ray KK, Cannon CP (2010) High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 55:1283-1299
35. Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M (2010) Molecular mechanisms of HDL-cholesterol elevation by statins and its effects of on HDL functions. J Atheroscler Thromb 17:436-451
36. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators (2007) Effects of toracetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122 (Pubitemid 350146106)
37. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tradif JC, Wright RS, dal OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089-2099
38. Investigators AIM-HIGH (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255-2267
39. Nichols GA, Vupputuri S, Rosales AG (2011) Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus. Am J Cardiol 108:1124-1128
40. Brown BG, Zhao XQ (2008) Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 101:58B-62B
41. Hewing B, Fisher EA (2012) Rationale for cholesteryl ester transfer protein inhibition. Curr Opin Lipidol 23:372-376
42. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A, FIELD study investigators (2009) The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care 32:493-498
43. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW (2002) Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162:2597-2604 (Pubitemid 35453499)